• info@diabetescareunit.com
  • +91 9601050191

Treatment of Diabetes Mellitus

Managing diabetes mellitus involves a combination of lifestyle adjustments, such as a healthy diet and regular exercise, alongside medication or insulin therapy to regulate blood sugar levels.

Treatment of diabetes mellitus differs from person to person and should be taken only as suggested by doctor.

Along with life style modification, following are the drugs used in the treatment of diabetes mellitus : ( JUST FOR BROAD INFORMATION )

DRUGS LOWERING INSULIN RESISTANCE :

BIGUANIDE : ( METFORMIN )

Metformin decreases hepatic glucose production, principally due to reduced gluconeogenesis and also through reduced glycogenolysis. It also increases the insulin-receptor binding and stimulates tissue uptake of glucose.

THIAZOLIDINEDIONES : ( PIOGLITAZONE )

Thiazolidinediones increase insulin mediated glucose uptake in muscle and increase adipogensis. It increases subcutaneous fat and not visceral, and hence, despite increase in adipogenesis it increase insulin sensitivity. It converts the larger adipocyte into smaller one. These convert small dense LDL into large LDL, increase HDL, decreases TG, decreases plasma free fatty acids.

DRUGS STIMULATING INSULIN RELEASE :

BIGSULPHONYLUREAS : ( GLIMEPRIDE, GLIPIZIDE, GLICLAZIDE, GLIBENCLAMIDE )

Sulphonylureas stimulate insulin release by blocking ATP sensitive potassium channels in the Beta cells, reducing potassium permeability. This causes depolarization of the cell and increases calcium entry, increasing insulin secretion.

NON SULPHONYLUREAS : MEGLITINIDES : ( REPAGLINIDE )

Meglitinides are similar to that of sulfonylureas in mechanism but they bind to a site on the SUR 1 sub unit of the beta cell ATP dependent potassium channel that is different from binding site for sulphonylureas.

GLP 1 ANALOGUES : EXENATIDE AND LIRAGLUTIDE

GLP 1 analogues bind to GLP 1 receptors and stimulate glucose dependent insulin release, therefore act as antihyperglycemics. They also suppress appetite and inhibit glucagon secretion. They slow gastric emptying and as a result prevent steep rise in post-prandial blood glucose levels.

DPP 4 INHIBITORS : ( SITAGLIPTIN, VIDAGLIPTIN, SAXAGLIPTIN, TENELIGLIPTIN )

Dpp-IV inhibitors slow the inactivation and degradation of GLP-1, a hormone involved in glucose removal from gut. Dpp-IV inhibitors improve blood glucose control and reduce both fasting and postprandial blood glucose levels, without causing weight gain.

DRUG REDUCING CARBOHYDRATE ABSORPTION :

ALPHA-GLUCOSIDASE INHIBITORS : ( ACARBOSE , VOGLIBOSE , MIGLITOL)

Alpha-glucosidase inhibitors are competitive suppressants of small intestine brush border alpha-glucosidases, which are essential to hydrolyse disaccharides, oligosaccharides, and polysaccharides to monosaccharides. Therefore, carbohydrate absorption and digestion is delayed and prolonged resulting in lowering of postprandial hyperglycemia. It also increases the secretion of GLP-1 ad decrease secretion of GIP.

DRUG DECREASING RENAL REABSORPTION OF GLUCOSE :

SGLT-2 INHIBITORS : ( CANAGLIFLOZIN, DAPAGLIFLOZIN, EMPAGLIFLOZIN )

Sodium glucose cotransporter-2 inhibitors, SGLT-2 INHIBITORS, inhibit SGLT-2 proteins located in the renal tubules of the kidneys which are responsible for reabsorbing glucose back into the blood. As a result, more glucose is excreted in the urine.

INSULIN THERAPY :

FAST ACTING : ( ASPART, LISPRO AND GLULISINE )

This type of insulin begins to work within 5 to 15 minutes and are active for 3 to 4 hours.

SHORT ACTING : ( REGULAR INSULIN – HUMAN )

INTERMEDIATE ACTING: ( NPH - NEUTRAL PROTAMINE HAGEDRON )

This type of insulin begins to work within 1 to 3 hours and is active for 16 to 24 hours.

LONG ACTING : ( GLARGINE AND DETEMIR )

This type of insulin begins to work within 1 to 2 hours and continue to be active, without major peaks or dips, for about 24 hours.

ULTRA-LONG ACTING : ( DEGLUDEC )

It begins to work within 30-90 minutes and continues to be active for greater than 24 hours.

INSULIN PUMPS :

Rather than receiving multiple daily subcutaneous injections of short and either long or intermediate acting insulin, patients using an insulin pump receive a continuous subcutaneous infusion of short acting insulin.

These devices hold insulin reservoir and supply insulin via a plastic tube into subcutaneous tissue.

Pumps are able to more precisely dose insulin compared to insulin syringes or pens. Pumps are also programmable to provide different doses of basal insulin throughout the day.

Newsletter

Subscribe to our newsletter


    Testimonials

    What our customers say?

    img
    img
    Devansh

    I enjoyed being an outpatient in your diabetes care unit. I experienced a staff that was cordial, warm and competent who treated me with the utmost care.

    img
    img
    S C Sony

    I have always been able to talk to a doctor and get my issues resolved. Coming to the diabetes care unit is like dealing with a trusted family.

    img
    img
    Alex

    Since time is limited, the 'Diabetes Care Unit' allows me to review general 'headlines' and dive deeper into the stories that interest me the most.

    img
    img
    Joe Biden

    I have been to the Diabetes Care Unit and have always been very satisfied with the care and attention I have received.

    img
    img
    Ankit

    Thank you! As always, thoroughly impressed with the information and support from the Diabetes Care Unit, you are all the best. Could hardly have managed without your constant support. I recommend this web site to everyone.